Assignee
NOVALIQ GMBH
DE·36 granted patents·28 pending applications·464 citations·filing 2006–2025
Top patents by PatentIndex Score
64 records- 0197US12128010B2Semifluorinated compounds and their compositionsNOVALIQ GMBH·Filed 2022·Granted Oct 29, 2024·6 cites·13 claims
- 0297US11357738B2Semifluorinated compounds and their compositionsNOVALIQ GMBH·Filed 2020·Granted Jun 14, 2022·15 cites·18 claims
- 0397US11154513B2Semifluorinated compoundsNOVALIQ GMBH·Filed 2016·Granted Oct 26, 2021·20 cites·18 claims
- 0497US10682315B2Semifluorinated compounds and their compositionsNOVALIQ GMBH·Filed 2018·Granted Jun 16, 2020·21 cites·12 claims
- 0596US11583513B2Semifluorinated alkane compositionsNOVALIQ GMBH·Filed 2020·Granted Feb 21, 2023·10 cites·12 claims
- 0696US10369117B2Compositions comprising mixtures of semifluorinated alkanesNOVALIQ GMBH·Filed 2017·Granted Aug 6, 2019·18 cites·9 claims
- 0796US10058615B2Semifluorinated alkane compositionsNOVALIQ GMBH·Filed 2017·Granted Aug 28, 2018·26 cites·9 claims
- 0896US9770508B2Semifluorinated alkane compositionsNOVALIQ GMBH·Filed 2013·Granted Sep 26, 2017·47 cites·20 claims
- 0995US12005033B2Compositions comprising mixtures of semifluorinated alkanesNOVALIQ GMBH·Filed 2019·Granted Jun 11, 2024·6 cites·24 claims
- 1095US11987623B2Stabilized antibody compositionsNOVALIQ GMBH·Filed 2021·Granted May 21, 2024·5 cites·20 claims
- 1195US11324757B2Pharmaceutical composition for treatment of increased intraocular pressureNOVALIQ GMBH·Filed 2019·Granted May 10, 2022·7 cites·17 claims
- 1295US10576154B2Semifluorinated alkane compositionsNOVALIQ GMBH·Filed 2018·Granted Mar 3, 2020·17 cites·19 claims
- 1395US10555953B2Pharmaceutical composition for treatment of increased intraocular pressureNOVALIQ GMBH·Filed 2019·Granted Feb 11, 2020·15 cites·17 claims
- 1495US9757460B2Stabilised protein compositions based on semifluorinated alkanesNOVALIQ GMBH·Filed 2013·Granted Sep 12, 2017·39 cites·16 claims
- 1594US11400132B2Ophthalmic compositions comprising ciclosporinNOVALIQ GMBH·Filed 2020·Granted Aug 2, 2022·8 cites·14 claims
- 1694US10449164B2Methods of treating ocular disorders using semifluorinated alkanesNOVALIQ GMBH·Filed 2013·Granted Oct 22, 2019·22 cites·11 claims
- 1793US11273174B2Iodine compositionsNOVALIQ GMBH·Filed 2018·Granted Mar 15, 2022·17 cites·23 claims
- 1893US10813976B2Ophthalmic compositions comprising ciclosporinNOVALIQ GMBH·Filed 2017·Granted Oct 27, 2020·20 cites·15 claims
- 1992US12059449B2Ophthalmic composition for treatment of dry eye diseaseNOVALIQ GMBH·Filed 2022·Granted Aug 13, 2024·5 cites·17 claims
- 2092US11413323B2Ophthalmic composition for treatment of dry eye diseaseNOVALIQ GMBH·Filed 2021·Granted Aug 16, 2022·10 cites·22 claims
- 2192US8029977B2Method for preserving organs or limbs using a composition containing a siloxane and a semifluorinated alkane and/or hydrofluoroetherNOVALIQ GMBH·Filed 2006·Granted Oct 4, 2011·47 cites·23 claims
- 2291US11723861B2Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseasesNOVALIQ GMBH·Filed 2018·Granted Aug 15, 2023·7 cites·13 claims
- 2390US11684589B2Pharmaceutical compositions for use in the therapy of blepharitisNOVALIQ GMBH·Filed 2017·Granted Jun 27, 2023·6 cites·12 claims
- 2490US10507132B2Topical administration methodNOVALIQ GMBH·Filed 2017·Granted Dec 17, 2019·22 cites·17 claims
- 2590US10273298B2Stabilized antibody compositionsNOVALIQ GMBH·Filed 2014·Granted Apr 30, 2019·16 cites·14 claims
- 2688US12226422B2Ophthalmic compositions comprising tafluprost for the treatment of glaucomaNOVALIQ GMBH·Filed 2019·Granted Feb 18, 2025·6 cites·19 claims
- 2787US2025345276A1O/w-emulsions comprising semifluorinated alkanesNOVALIQ GMBH·Filed 2025·Application pending·0 cites
- 2886US11278503B2Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditionsNOVALIQ GMBH·Filed 2018·Granted Mar 22, 2022·7 cites·9 claims
- 2986US2025017872A1Semifluorinated compounds and their compositionsNOVALIQ GMBH·Filed 2024·Application pending·0 cites
- 3085US11896559B2Opthalmic compositions comprising F6H8NOVALIQ GMBH·Filed 2018·Granted Feb 13, 2024·7 cites·20 claims
- 3184US2024350425A1Compositions comprising mixtures of semifluorinated alkanesNOVALIQ GMBH·Filed 2024·Application pending·0 cites
- 3283US11576893B2Pharmaceutical compositions comprising nebivololNOVALIQ GMBH·Filed 2019·Granted Feb 14, 2023·7 cites·21 claims
- 3383US2023139672A1O/w-emulsions comprising semifluorinated alkanesNOVALIQ GMBH·Filed 2022·Application pending·0 cites
- 3481US2026091084A1Ophthalmic composition for treatment of dry eye diseaseNOVALIQ GMBH·Filed 2025·Application pending·0 cites
- 3581US2023330056A1Semifluorinated alkane compositionsNOVALIQ GMBH·Filed 2023·Application pending·0 cites
- 3678USRE50060ETopical administration methodNOVALIQ GMBH·Filed 2017·Granted Jul 30, 2024·5 cites·49 claims
- 3776US12569452B2Ophthalmic compositions comprising F6H8NOVALIQ GMBH·Filed 2024·Granted Mar 10, 2026·0 cites·21 claims
- 3873US12496326B2Ophthalmic composition for treatment of dry eye diseaseNOVALIQ GMBH·Filed 2022·Granted Dec 16, 2025·0 cites·16 claims
- 3971US2020360285A1O/w-emulsions comprising semifluorinated alkanesNOVALIQ GMBH·Filed 2020·Application pending·0 cites
- 4071US2024374678A1Ophthalmic composition for treatment of dry eye diseaseNOVALIQ GMBH·Filed 2024·Application pending·0 cites
- 4171US2022354926A1Ophthalmic compositions comprising ciclosporinNOVALIQ GMBH·Filed 2022·Application pending·0 cites
- 4270US2023398065A1Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseasesNOVALIQ GMBH·Filed 2023·Application pending·0 cites
- 4366US2019224123A1O/w-emulsions comprising semifluorinated alkanesNOVALIQ GMBH·Filed 2019·Application pending·0 cites
- 4464US2021315832A1Semifluorinated compoundsNOVALIQ GMBH·Filed 2021·Application pending·0 cites
- 4563USRE49758EStabilised protein compositions based on semifluorinated alkanesNOVALIQ GMBH·Filed 2013·Granted Dec 19, 2023·0 cites·35 claims
- 4663US2025295607A1Ophthalmic compositions for treatment of ocular surface damage and symptoms of drynessNOVALIQ GMBH·Filed 2025·Application pending·0 cites
- 4760US2022079925A1Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseasesNOVALIQ GMBH·Filed 2021·Application pending·0 cites
- 4857US2018360908A1Ophthalmic composition for treatment of dry eye diseaseNOVALIQ GMBH·Filed 2018·Application pending·0 cites
- 4957US2017087100A1Semifluorinated compounds and their compositionsNOVALIQ GMBH·Filed 2016·Application pending·0 cites
- 5056US12419933B2Ophthalmic composition for the treatment of uveitisNOVALIQ GMBH·Filed 2020·Granted Sep 23, 2025·0 cites·17 claims
Showing the top 50 of 64 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when NOVALIQ GMBH files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →